Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Park, E K ^a   Lee, J C ^b   Park, J W ^a   Bang, S Y ^a   Yi, S A ^a   Kim, B K ^a   Park, J H ^a   Kwon, S H ^c   You, J S ^d   Nam, S W ^e   Cho, E J ^a   Han, J W ^a  

^a Sungkyunkwan University   (South Korea)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yonsei University   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; HISTONE DEACETYLASE 1; HISTONE H3; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER STEM CELL; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE REPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; CYTOLOGY; GENETICS; HELA CELL LINE; JURKAT CELL LINE; MCF-7 CELL LINE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

AC133 ANTIGEN; ANTIGENS, CD; BIOMARKERS, TUMOR; CELL LINE, TUMOR; GLYCOPROTEINS; HELA CELLS; HUMANS; JURKAT CELLS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; PEPTIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84946554548     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.313     Document Type: Article

References (58)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
2. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
3. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006; 24: 2603-2610.
4. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14: 450-460.
5. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
6. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009; 18: 1127-1134.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
8. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174.
9. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012; 2012: 708036.
10. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021.
11. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012.
12. Peh GS, Lang RJ, Pera MF, Hawes SM. CD133 expression by neural progenitors derived from human embryonic stem cells and its use for their prospective isolation. Stem Cells Dev 2009; 18: 269-282.
13. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10: R10.
14. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545.
15. Yin S, Li J, Hu C, Chen X, Yao M, Yan M et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450.
16. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-2883.
17. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
18. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
19. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
20. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012; 55: 807-820.
21. Olovnikov IA, Kravchenko JE, Chumakov PM. Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol 2009; 19: 32-41.
22. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332-337.
23. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res 2007; 35: 7475-7484.
24. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455.
25. Jerry DJ, Tao L, Yan H. Regulation of cancer stem cells by p53. Breast Cancer Res 2008; 10: 304.
26. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62-73.
27. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005; 7: 165-171.
28. You JS, Kang JK, Seo DW, Park JH, Park JW, Lee JC et al. Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Res 2009; 69: 5716-5725.
29. Kato S, Han SY, Liu W, Otsuka K, Shibata H et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 14: 8424-8429.
30. Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing geneticinstability. Oncogene 2010; 7: 949-956.
31. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004; 103: 2055-2061.
32. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001; 276: 27716-27720.
33. Estève PO, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci USA 2005; 102: 1000-1005.
34. Banerjee T, Nath S, Roychoudhury S. DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling. Nucleic Acids Res 2009; 37: 2688-2698.
35. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 30: 3833-3845.
36. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-10444.
37. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014; 511: 246-250.
38. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 2008; 3: e3769.
39. Li K, Liu C, Zhou B, Bi L, Huang H, Lin T et al. Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci 2013; 14: 11981-11993.
40. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
41. Zhang Y, Toh L, Lau P,Wang X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem 2012; 287: 32494-32511.
42. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 2007; 67: 194-201.
43. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW et al. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998; 17: 419-424.
44. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
45. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
46. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
47. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674-4682.
48. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008; 18: 1037-1046.
49. Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene 2013; 32: 3119-3129.
50. You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010; 51: 1635-1644.
51. Martin M, Ancey PB, Cros MP, Durand G, Le Calvez-Kelm F, Hernandez-Vargas H et al. Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. BMC Genomics 2014; 15: 435.
52. Li Y, Jiang F, Liu Q, Shen J, Wang X, Li Z et al. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Toxicol Sci 2015; 143: 156-164.
53. Chang Y, Sun L, Kokura K, Horton JR, Fukuda M, Espejo A et al. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. Nat Commun 2011; 2: 533.
54. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003; 31: 2305-2312.
55. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
56. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA 2013; 110: 6829-6834.
57. Lee JC, Kang SU, Jeon Y, Park JW, You JS, Ha SW et al. Protein L-isoaspartyl methyltransferase regulates p53 activity. Nat Commun 2012; 3: 927.
58. Bang SY, Kwon SH, Yi SH, Yi SA, Park EK, Lee JC et al. Epigenetic activation of the foxa2 gene is required for maintaining the potential of neural precursor cells to differentiate into dopaminergic neurons after expansion. Stem Cells Dev 2015; 24: 520-533.